IBB0979 with topotecan for relapsed small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding IBB0979 (an experimental immunotherapy) to standard chemotherapy (topotecan) works better than topotecan alone for people whose small cell lung cancer has returned or worsened after prior treatment. It aims to find a new option for patients who have limited options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have small cell lung cancer that has come back or worsened after at least one round of chemotherapy.
- You can still perform daily activities with little or no help (ECOG 0 or 1).
- You have at least one tumor that can be measured on scans.
- You do not have active brain metastases or serious heart or lung problems.
- You have not had other cancer treatments in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IBI3009 for people with advanced small cell lung cancer that cannot be removed by surgery. It aims to see how safe the drug is and how well it works against the cancer.
This trial tests a new drug called HS-20093 against a standard drug (topotecan) for people with small cell lung cancer that has returned after initial treatment. The goal is to see which drug works better.
This trial tests a new drug, JK-1201I, against a standard treatment (topotecan) for people with extensive-stage small cell lung cancer that came back after platinum-based chemotherapy. It aims to see if the new drug works better at controlling the cancer.
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
This trial tests an experimental drug called IBB0979 for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the right dose and see if the drug can shrink tumors.
This trial tests a new drug called MHB088C for people with small cell lung cancer that has come back or gotten worse after standard treatments. It compares this drug to other options your doctor might choose. The goal is to see if MHB088C works better.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.